Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
11 mars 2025 07h30 HE
|
Achieve Life Sciences
Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER,...
Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference
07 mars 2025 08h30 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, March 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global...
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025
06 mars 2025 08h30 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global...
Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference
11 févr. 2025 08h30 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development...
Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial
10 févr. 2025 08h30 HE
|
Achieve Life Sciences
No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025 SEATTLE and VANCOUVER, British Columbia, Feb. 10,...
Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors
10 janv. 2025 08h30 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the global development and...
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission
07 janv. 2025 08h30 HE
|
Achieve Life Sciences
Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission ORCA-OL Long-Term...
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
06 janv. 2025 08h30 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and...
Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer
09 déc. 2024 08h30 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and...
Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA
03 déc. 2024 08h30 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and...